FDA Clears First Human Study of DYNE-302

Company Dyne Therapeutics Event Type Regulatory Clearance (FDA, First-in-Human Phase I) Modality TfR1-targeted siRNA conjugate (FORCE delivery platform) Asset DYNE-302 Target DUX4 transcriptome (via TfR1-mediated muscle delivery) Disease Area Facioscapulohumeral muscular dystrophy (FSHD) Summary FDA cleared Dyne Therapeutics to begin a randomized Phase I study…